Statistics from Altmetric.com
Q In patients with type 2 diabetes and evidence of macrovascular disease, does pioglitazone reduce all cause mortality and macrovascular complications?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆
randomised placebo controlled trial (PROactive study).
blinded (clinicians, patients, data collectors, and outcome assessors).*
Follow up period
mean 34.5 months.
321 centres (including communities and hospitals) in 19 European countries.
5238 patients 35–75 years of age (mean age 62 y, 66% men) who had type 2 diabetes, haemoglobin A1c concentration ⩾6.5%, and ⩾1 of the following criteria: myocardial infarction (MI), stroke, percutaneous coronary intervention or coronary artery bypass surgery ⩾6 months previously, acute coronary syndrome ⩾3 months previously, or objective evidence …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.